Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNF | P01375 | 1/20 | 0.48 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.42 |
| ▸ | CNR2 | P34972 | 10/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18032509 | 0.93 | TNF (0.55) | TNFPIK3CDHRH3CNR2HDAC1 | |
| SCHEMBL18032516 | 0.91 | TNF (0.42) | TNFPIK3CDHRH3CNR2HDAC1 | |
| SCHEMBL18032514 | 0.91 | HRH3 (0.46) | TNFPIK3CDHRH3CNR2HDAC1 | |
| SCHEMBL18032511 | 0.86 | PIK3CD (0.52) | TNFPIK3CDHRH3CNR2HDAC1 | |
| SCHEMBL18032506 | 0.85 | TNF (0.41) | TNFPIK3CDHRH3CNR2HDAC1 | |
| SCHEMBL18032512 | 0.83 | HDAC1 (0.42) | TNFPIK3CDHRH3CNR2HDAC1 | |
| SCHEMBL362572 | 0.81 | PIK3CD (0.42) | TNFPIK3CDHRH3CNR2HDAC1 | |
| SCHEMBL357787 | 0.80 | PIK3CD (0.44) | TNFPIK3CDHDAC1SMN1; SMN2PIK3CA | |
| SCHEMBL359280 | 0.78 | PIK3CD (0.64) | TNFPIK3CDPIK3CA | |
| SCHEMBL2674843 | 0.77 | HRH3 (0.46) | PIK3CDHRH3HDAC1PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2593455-B1 | PURINE COMPOUNDS SELECTIVE FOR I3 P110 DELTA, AND METHODS OF USE | HOFFMANN LA ROCHE (CH) | 2015-03-18 | — | — | EP | disclosed |
| EP-2593455-A1 | PURINE COMPOUNDS SELECTIVE FOR I3 P110 DELTA, AND METHODS OF USE | F.HOFFMANN-LA ROCHE AG (CH) | 2013-05-22 | — | — | EP | disclosed |
| US-8293736-B2 | Purine compounds selective for PI3K P110 delta, and methods of use | F. HOFFMANN LA ROCHE AG (CH) | 2012-10-23 | — | — | US | disclosed |
| US-8293736-B2 | Purine compounds selective for PI3K P110 delta, and methods of use | F. HOFFMANN LA ROCHE AG (CH) | 2012-10-23 | — | — | US | disclosed |
| US-8293736-B2 | Purine compounds selective for PI3K P110 delta, and methods of use | F. HOFFMANN LA ROCHE AG (CH) | 2012-10-23 | — | — | US | disclosed |
| US-20120015931-A1 | PURINE COMPOUNDS SELECTIVE FOR PI3K P110 DELTA, AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2012-01-19 | — | — | US | disclosed |
| US-20120015931-A1 | PURINE COMPOUNDS SELECTIVE FOR PI3K P110 DELTA, AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2012-01-19 | — | — | US | disclosed |
| US-20120015931-A1 | PURINE COMPOUNDS SELECTIVE FOR PI3K P110 DELTA, AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2012-01-19 | — | — | US | disclosed |
| WO-2012007493-A1 | PURINE COMPOUNDS SELECTIVE FOR ΡI3Κ P110 DELTA, AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2012-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015931-A1 | PURINE COMPOUNDS SELECTIVE FOR PI3K P110 DELTA, AND METHODS OF USE | PIK3CA, PIK3CD, PIK3CG | TNF 1800/4885PIK3CD 2/4885HRH3 1331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.